114 related articles for article (PubMed ID: 19718945)
1. Evaluation of fluoren-NU as a novel antitumor agent.
Mukherjee A; Dutta S; Chashoo G; Bhagat M; Saxena AK; Sanyal U
Oncol Res; 2009; 17(9):387-96. PubMed ID: 19718945
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dimethoxydop-NU as a novel anti-tumor agent.
Mukherjee A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2007 Dec; 26(4):489-97. PubMed ID: 18365543
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent.
Samanta S; Pain A; Dutta S; Saxena AK; Shanmugavel M; Pandita RM; Qazi GN; Sanyal U
J Exp Ther Oncol; 2005; 5(1):15-22. PubMed ID: 16416597
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of naphthal-NU, a 2-chloroethylnitrosourea derivative of naphthalimide, as a mixed-function anticancer agent.
Samanta S; Pain A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2002 Mar; 21(1):87-93. PubMed ID: 12071535
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of naphthalmustine, a nitrogen mustard derivative of naphthalimide as a rationally-designed anticancer agent.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Qazi GN; Sanyal U
J Exp Clin Cancer Res; 2003 Sep; 22(3):411-8. PubMed ID: 14582700
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antitumor efficacy and toxicity of novel 6-nitro-2-(3-chloropropyl)-1H-benz[de]isoquinoline-1,3-dione in vivo in mouse.
Mukherjee A; Dutta S; Sanyal U
J Cancer Res Ther; 2013; 9(3):442-6. PubMed ID: 24125980
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of beta-tethymustine, a new anticancer compound, in murine tumour models.
Ghosh M; Bhattacharya S; Sadhu U; Dutta S; Sanyal U
Cancer Lett; 1997 Oct; 119(1):7-12. PubMed ID: 18372515
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of 2-chloroethylnitrosoureas of substituted naphthalimides as mixed-function anticancer compounds.
Samanta S; Pain A; Dutta S; Sanyal U
Acta Pol Pharm; 2001; 58(5):351-6. PubMed ID: 11876442
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 'cypenhymustine', a new anticancer compound, in murine tumour models.
Sanyal U; Bhattacharya S; Sadhu U; Dutta S; Das H; Ghosh M
Cancer Lett; 1993 Jun; 70(1-2):1-6. PubMed ID: 8330289
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of toxicity of cypenhymustine, a new anticancer compound, in mice.
Sadhu U; Ghosh M; Bhattacharya S; Dutta S; Das H; Sanyal U
Cancer Lett; 1994 Sep; 85(1):65-72. PubMed ID: 7923104
[TBL] [Abstract][Full Text] [Related]
13. Effect of 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea on experimental tumors.
Akaike Y; Arai Y; Taguchi H; Satoh H
Gan; 1982 Jun; 73(3):480-7. PubMed ID: 7129012
[TBL] [Abstract][Full Text] [Related]
14. CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties.
Schieweck K; Stanek J; Kanter PM; Schmidt-Ruppin KH; Müller M; Matter A
Cancer Chemother Pharmacol; 1989; 23(6):341-7. PubMed ID: 2713956
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and toxicity of methyl 6-[3-(2-chloroethyl)- 3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in experimental animals.
Fujimoto S; Tashiro T; Ogawa M
Gan; 1984 Oct; 75(10):937-46. PubMed ID: 6510639
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
17. A new nitrosourea derivative TA-077, 1-(2-chloroethyl)-3-isobutyl-3-(beta-maltosyl)-1-nitrosourea. I. Comparative study on antitumor activity.
Fujimoto S; Ogawa M
Cancer Chemother Pharmacol; 1982; 9(3):134-9. PubMed ID: 6218931
[TBL] [Abstract][Full Text] [Related]
18. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
[TBL] [Abstract][Full Text] [Related]
19. Experimental and clinical studies of the antitumor activity of 1-methyl-1-nitrosourea (NSC-23909).
Emanuel NM; Vermel EM; Ostrovskaya LA; Korman NP
Cancer Chemother Rep; 1974; 58(2):135-48. PubMed ID: 4830495
[No Abstract] [Full Text] [Related]
20. Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.
Ali-Osman F; Giblin J; Berger M; Murphy MJ; Rosenblum ML
Cancer Res; 1985 Sep; 45(9):4185-91. PubMed ID: 2411398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
